[1] Qi J, Li M, Wang L, et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data[J]. Lancet Public Health, 2023, 8: e943-e955. [2] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72: 7-33. [3] Flugel CL, Majzner RG, Krenciute G, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours[J]. Nat Rev Clin Oncol, 2023, 20: 49-62. [4] Whitesell L, Lindquist SL. Hsp90 and the chaperoning of cancer[J]. Nat Rev Cancer, 2005, 5: 761-772. [5] Ciocca DR, Clark GM, Tandon AK, et al. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications[J]. J Natl Cancer Inst, 1993, 85: 570-574. [6] Conroy SE, Sasieni PD, Fentiman I, et al. Autoanti-bodies to the 90kDa heat shock protein and poor survival in breast cancer patients[J]. Eur J Cancer, 1998, 34: 942-943. [7] Kimura E, Enns RE, Alcaraz JE, et al. Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein Hsp-60[J]. J Clin Oncol, 1993, 11: 891-898. [8] Ralhan R, Kaur J. Differential expression of Mr 70,000 heat shock protein in normal, premalignant, and malignant human uterine cervix[J]. Clin Cancer Res, 1995, 1: 1217-1222. [9] Santarosa M, Favaro D, Quaia M, et al. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients[J]. Eur J Cancer, 1997, 33: 873-877. [10] Sidera K, Patsavoudi E. Extracellular Hsp90: conquering the cell surface[J]. Cell Cycle, 2008, 7: 1564-1568. [11] Mondal SB, O′brien CM, Bishop K, et al. Repurposing molecular imaging and sensing for cancer image-guided surgery[J]. J Nucl Med, 2020, 61: 1113-1122. [12] Rowe SP, Pomper MG. Molecular imaging in oncology: current impact and future directions[J]. CA Cancer J Clin, 2022, 72: 333-352. [13] Gao M, Yu F, Lv C, et al. Fluorescent chemical probes for accurate tumor diagnosis and targeting therapy[J]. Chem Soc Rev, 2017, 46: 2237-2271. [14] Kijanka M, Warnders FJ, El Khattabi M, et al. Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery[J]. Eur J Nucl Med Mol Imaging, 2013, 40: 1718-1729. [15] Predina JD, Newton AD, Connolly C, et al. Identification of a folate receptor-targeted near-infrared molecular contrast agent to localize pulmonary adenocarcinomas[J]. Mol Ther, 2018, 26: 390-403. |